一贯煎加减联合恩替卡韦治疗代偿性肝硬化的疗效观察  

Observation on the therapeutic effect of modified Yiguanjian combined with Entecavir in the treatment of compensatory cirrhosis

作　　者：董蒙芸 DONG Mengyun(Infection Department of the Fifth People's Hospital of Huai'an,Huaian,Jiangsu 223300,China)

机构地区：[1]淮安市第五人民医院感染科,江苏淮安223300

出　　处：《中国国境卫生检疫杂志》2023年第S01期40-42,共3页Chinese Journal of Frontier Health and Quarantine

摘　　要：目的探讨一贯煎加减联合恩替卡韦治疗代偿性乙肝肝硬化的临床疗效。方法选取2020年6月-2022年6月我院收治代偿期乙肝肝硬化阴虚血瘀证患者共78例纳人研究,将其随机分为观察组及对照组各39例。其中对照组患者给予恩替卡韦片口服治疗,观察组予一贯煎加减联合恩替卡韦治疗,两组患者的治疗周期均为12周。比较治疗前后两组患者的肝功能变化情况,并比较两组患者的中医证候疗效。结果治疗前,观察组及对照组的ALT、AST、TBIL水平差异无统计学意义(P>0.05);疗程结束后,两组患者ALT、AST、TBIL水平均明显低于治疗前,且观察组明显低于对照组(P<0.05)。观察组的中医证候总有效率明显高于对照组,差异有统计学意义(P<0.05)。结论一贯煎加减联合恩替卡韦对代偿期乙肝肝硬化阴虚血瘀证患者疗效显著,可以有效修复患者受损肝功能,提高临床疗效。Objective To explore the clinical eficacy of Yiguanjian plus Entecavir in the treatment of compensatory hepatitis B cirrhosis.Methods From June 2020 to June 2022,a total of 78 patients with yin deficiency and blood stasis syndrome of compensated hepatitis B cirrhosis admitted to our hospital were included in the study,and they were randomly divided into the observation group and the control group,with 39 cases in each group.The patients in the control group were treated with Entecavir tablets orally,and the patients in the observation group were treated with Yiguan Decoction plus Entecavir.The treatment cycle of both groups was 12 weeks.Compare the changes in liver function between the two groups of patients before and after treatment,and compare the therapeutie effects of traditional Chinese medicine syndromes between the two groups of patients.Results Before treatment,there was no significant difference in the levels of ALT,AST,and TBIL between the observation group and the control group(P>0.05).After the treatment,the levels of ALT,AST,and TBIL in both groups of patients were significantly lower than before treatment,and the observation group was significantly lower than the control group,with P<0.05.The total effective rate of traditional Chinese medicine syndromes in the observation group was significantly higher than that in the control group,and the difference between the two groups was statistically significant(P<0.05).Conclusion Tongyi decoction plus Entecavir has a significant ffct on patients with compensated hepatitis B cirrhosis with yin deficiency and blood stasis syndrome,which can ffectively repair the damaged liver function of patients,improve elinical efficacy,and has promotional value.

关 键 词：代偿性乙肝肝硬化 一贯煎 恩替卡韦 联合治疗 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]